Table 2. Results of meta-analysis of blood vessel invasion and prognosis in NSCLC.

Groups	Estimate of relative hazard			Homogeneity test
	HR	95% CI	p	Q (df)	p
All studies
Unadjusted OS (31 studies, n = 8,528)	2.22	1.93–2.56	<0.0001	79.63 (33)	<0.001
Adjusted OS (28 studies, n = 9,873)	1.90	1.65–2.19	<0.0001	84.40 (28)	<0.001
Unadjusted RFS (11 studies, n = 4,498 )	3.28	2.14–5.05	<0.0001	90.00 (10)	<0.001
Adjusted RFS (7 studies, n = 3,088)	3.98	2.24–7.06	<0.0001	34.44 (6)	<0.001
Stage I studies
Unadjusted OS (14 studies, n = 2,908 )	2.94	2.28–3.80	<0.0001	22.83 (13)	0.044
Adjusted OS (13 studies, n = 3,974)	2.15	1.68–2.75	<0.0001	26.70 (12)	0.009
Unadjusted RFS (5 studies, n = 647)	5.89	3.98–8.71	<0.0001	3.76 (4)	0.440
Adjusted RFS (4 studies, n = 576)	6.93	4.23–11.37	<0.0001	3.61 (3)	0.306

NSCLC = non-small-cell lung cancer; HR = hazard ratio; CI = confidence interval; OS = overall survival; RFS = relapse-free survival.